Provided by Tiger Trade Technology Pte. Ltd.

Editas Medicine

2.34
-0.0100-0.43%
Volume:1.17M
Turnover:2.80M
Market Cap:228.43M
PE:-1.00
High:2.46
Open:2.37
Low:2.34
Close:2.35
52wk High:4.54
52wk Low:0.9101
Shares:97.62M
Float Shares:89.58M
Volume Ratio:0.62
T/O Rate:1.30%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3493
EPS(LYR):-2.8795
ROE:-211.37%
ROA:-28.26%
PB:16.98
PE(LYR):-0.81

Loading ...

Chardan Capital Upgrades Editas Medicine to Buy From Neutral, Price Target is $3.50

MT Newswires Live
·
Nov 13

Editas Medicine price target lowered to $3.50 from $12 at Chardan

TIPRANKS
·
Nov 13

Cautious Hold Rating on Editas Medicine Amid Promising Preclinical Results and Development Uncertainties

TIPRANKS
·
Nov 12

Analysts Offer Insights on Healthcare Companies: Editas Medicine (EDIT) and Guardian Pharmacy Services, Inc. Class A (GRDN)

TIPRANKS
·
Nov 11

Barclays Keeps Their Hold Rating on Editas Medicine (EDIT)

TIPRANKS
·
Nov 11

Editas Medicine Reports Q3 2025 Progress and Financials

TIPRANKS
·
Nov 11

Editas Medicine Q3 EPS $(0.28) Beats $(0.29) Estimate, Sales $7.543M Beat $5.020M Estimate

Benzinga
·
Nov 10

Editas Medicine Q3 net loss narrows, beats expectations

Reuters
·
Nov 10

Editas Medicine Reports Q3 2025 Results and Advances EDIT-401 Toward Human Trials

Reuters
·
Nov 10

BRIEF-Editas Medicine Q3 Net Income USD -25.117 Million Vs. IBES Estimate USD -28.1 Million

Reuters
·
Nov 10

Editas Medicine Announces Third Quarter 2025 Results and Business Updates

THOMSON REUTERS
·
Nov 10

Editas Medicine Inc: on Track to Submit Ind/Cta for Edit-401 by Mid-2026, Achieve Initial Human Proof-of-Concept Data by Year-End 2026

THOMSON REUTERS
·
Nov 10

Editas Medicine Q3 Operating Income USD -24.548 Million

THOMSON REUTERS
·
Nov 10

Editas Medicine Q3 Net Income USD -25.117 Million VS. Ibes Estimate USD -28.1 Million

THOMSON REUTERS
·
Nov 10

Press Release: ONE Gas Announces Third Quarter 2025 Financial Results; Narrows 2025 Financial Guidance

Dow Jones
·
Nov 04

Editas Medicine Unveils Promising In Vivo CRISPR Cholesterol Therapy at AHA 2025

Reuters
·
Nov 03

Editas Medicine Inc expected to post a loss of 30 cents a share - Earnings Preview

Reuters
·
Oct 31

Editas Medicine’s Long-Term Study on EDIT-301: A Potential Game-Changer for Hemoglobinopathies

TIPRANKS
·
Oct 28

Editas Medicine management to meet with Cantor

TIPRANKS
·
Oct 24

H.C. Wainwright Sticks to Its Buy Rating for Editas Medicine (EDIT)

TIPRANKS
·
Oct 22